Immunexpress Announces U.S. FDA Clearance of EDTA Blood Compatible Cartridges for SeptiCyte RAPID®
SEATTLE and BRISBANE, Australia, Jan. 4, 2024 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the clearance of EDTA blood compatible cartridges by the U.S. Food and Drug Administration (FDA) for use with SeptiCyte RAPID®. The updated SeptiCyte® RAPID cartridges add undiluted EDTA blood as a validated sample type within the U.S. healthcare market and have been available on the European market since August 2022.
- SEATTLE and BRISBANE, Australia, Jan. 4, 2024 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the clearance of EDTA blood compatible cartridges by the U.S. Food and Drug Administration (FDA) for use with SeptiCyte RAPID®.
- The updated SeptiCyte® RAPID cartridges add undiluted EDTA blood as a validated sample type within the U.S. healthcare market and have been available on the European market since August 2022.
- Their implementation allows for the use of standard EDTA blood collection tubes in place of proprietary PAXgene® blood RNA tubes.
- BARDA awarded this grant to Immunexpress in 2020 as part of the DRIVe Solving Sepsis program.